Skip to content

Moderna MRNA Total Liabilities

Total Liabilities at other companies

Pfizer logo
PfizerPFE
$3.41B-97.1%
Novavax logo
NovavaxNVAX
$1.19B-13.2%
ALN
Alnylam PharmaceuticalsALNY
$4.2B-2.6%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$1.53B+31.4%
Roivant Sciences logo
Roivant SciencesROIV
$416.28M+66.7%
Vaxcyte, Inc. logo
Vaxcyte, Inc.PCVX
$352.29M+97.8%

Other financials

Income statement

See full
Revenue$389.0M+260%
Gross profit-$566.0M-3,244%
Operating income-$1.4B-32.2%
Net income-$1.3B-38.3%
EPS (diluted)-$3.40-34.9%

Balance sheet

See full
Cash & equivalents$1.9B+17.4%
Total debt$1.3B+71.9%
Total equity$7.4B-26.4%
Total assets$11.5B-9.6%

Cash flow

See full
Operating cash flow-$630.0M+39.2%
CapEx$62.0M-47.0%
Free cash flow-$692.0M+40.0%

Valuation

See full
Market cap$22.14B+73.9%
Enterprise value$21.56B+76.5%
P/S10×+5.8×

Profitability

See full
Gross margin22.1%-32.0pp
Operating margin-153.3%+67.8pp
Net margin-143.6%+80.2pp
FCF margin-132.4%

Returns & leverage

See full
Return on equity-36.6%+11.9pp
Debt / equity0.2×+0.1×
Current ratio2.4×-1.8×

Where this comes from

Reported directly by Moderna in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The official record: Moderna’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about Moderna's total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Moderna's total liabilities?
Moderna (MRNA) reported total liabilities of $4.08B in Q1 2026.
How has Moderna's total liabilities changed year-over-year?
Moderna's total liabilities increased by 54.7% year-over-year, from $2.64B to $4.08B.
What is the long-term trend for Moderna's total liabilities?
Over 5 years (2020 to 2025), Moderna's total liabilities has grown at a -5.0% compound annual growth rate (CAGR), from $4.78B to $3.69B.
What does total liabilities mean?
The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.